CRISPR Therapeutics AG
For the period ended Dec 31, 2024. Filed Feb 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 11, 2025
CRSP$50.04-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $298,257 | $389,477 |
| Marketable securities | 1,605,569 | 1,304,215 |
| Accounts receivable | 25,000 | 200,000 |
| Prepaid expenses and other current assets | 8,306 | 14,386 |
| Total current assets | 1,937,132 | 1,908,078 |
| Property and equipment, net | 134,093 | 151,945 |
| Marketable securities, non-current | — | 1,973 |
| Intangible assets, net | — | 16 |
| Restricted cash | 11,519 | 11,591 |
| Operating lease assets | 143,461 | 153,993 |
| Other non-current assets | 15,829 | 1,975 |
| Total assets | $2,242,034 | $2,229,571 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $14,709 | $38,147 |
| Accrued expenses | 41,072 | 45,335 |
| Deferred revenue, current | 3,845 | 4,105 |
| Accrued tax liabilities | 451 | 438 |
| Operating lease liabilities | 17,288 | 15,625 |
| Other current liabilities | 10,417 | 5,141 |
| Total current liabilities | 87,782 | 108,791 |
| Deferred revenue, non-current | 12,323 | 14,012 |
| Operating lease liabilities, net of current portion | 206,405 | 223,007 |
| Other non-current liabilities | 3,444 | 958 |
| Total liabilities | 309,954 | 346,768 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ equity: | ||
| Common shares, CHF 0.03 nominal value, 132,477,166 and 126,536,183 shares authorized at December 31, 2024 and December 31, 2023, respectively, 85,912,297 and 80,214,694 shares issued at December 31, 2024 and December 31, 2023, respectively, 85,741,981 and 80,044,378 shares outstanding at December 31, 2024 and December 31, 2023, respectively | 2,698 | 2,497 |
| Treasury shares, at cost, 170,316 shares at December 31, 2024 and at December 31, 2023 | (62) | (62) |
| Additional paid-in capital | 3,293,556 | 2,878,155 |
| Accumulated deficit | (1,365,952) | (999,700) |
| Accumulated other comprehensive income | 1,840 | 1,913 |
| Total shareholders’ equity | 1,932,080 | 1,882,803 |
| Total liabilities and shareholders’ equity | $2,242,034 | $2,229,571 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.